S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:VALN

Valneva (VALN) Stock Price, News & Analysis

$7.92
-0.04 (-0.50%)
(As of 03/28/2024 ET)
Today's Range
$7.73
$8.00
50-Day Range
$6.63
$9.02
52-Week Range
$6.58
$17.05
Volume
4,629 shs
Average Volume
17,189 shs
Market Capitalization
$550.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.67

Valneva MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
173.6% Upside
$21.67 Price Target
Short Interest
Bearish
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.12mentions of Valneva in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.11 to ($1.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.24 out of 5 stars

Medical Sector

797th out of 939 stocks

Biological Products, Except Diagnostic Industry

134th out of 158 stocks

VALN stock logo

About Valneva Stock (NASDAQ:VALN)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

VALN Stock Price History

VALN Stock News Headlines

Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Valneva SE (VALN) Q4 2023 Earnings Call Transcript
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
What Analysts Are Saying About Valneva Stock
Valneva's (VALN) "Buy" Rating Reiterated at HC Wainwright
See More Headlines
Receive VALN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/29/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VALN
Fax
N/A
Employees
676
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.67
High Stock Price Target
$26.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+173.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-109,780,000.00
Pretax Margin
-64.16%

Debt

Sales & Book Value

Annual Sales
$165.52 million
Book Value
$2.00 per share

Miscellaneous

Free Float
59,100,000
Market Cap
$550.12 million
Optionable
Not Optionable
Beta
2.23
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Thomas Lingelbach (Age 61)
    President, CEO & Director
    Comp: $996.05k
  • Mr. Peter Buhler (Age 53)
    Chief Financial Officer
    Comp: $605.32k
  • Mr. Franck Grimaud MBA (Age 57)
    Chief Business Officer
    Comp: $434.73k
  • Dr. Juan-Carlos Jaramillo M.D. (Age 52)
    Chief Medical Officer
    Comp: $584.65k
  • Ms. Dipal Patel (Age 49)
    Chief Commercial Officer
    Comp: $559.74k
  • Mr. Joshua Drumm Ph.D.
    Vice President of Investor Relations
  • Ms. Laetitia Bachelot-Fontaine
    VP of Global Communications & European Investor Relations
  • Mr. Christian Taucher
    Head of Global Medical Affairs
  • Ms. Susanne Eder-Lingelbach
    Head of Clinical Operations
  • Katrin Dubischar
    VP & Program Director of Chikungunya Vaccine

VALN Stock Analysis - Frequently Asked Questions

Should I buy or sell Valneva stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VALN shares.
View VALN analyst ratings
or view top-rated stocks.

What is Valneva's stock price target for 2024?

3 brokerages have issued 1 year price targets for Valneva's shares. Their VALN share price targets range from $17.00 to $26.00. On average, they expect the company's stock price to reach $21.67 in the next twelve months. This suggests a possible upside of 173.6% from the stock's current price.
View analysts price targets for VALN
or view top-rated stocks among Wall Street analysts.

How have VALN shares performed in 2024?

Valneva's stock was trading at $10.37 at the start of the year. Since then, VALN stock has decreased by 23.6% and is now trading at $7.92.
View the best growth stocks for 2024 here
.

Are investors shorting Valneva?

Valneva saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 42,400 shares, an increase of 49.8% from the February 29th total of 28,300 shares. Based on an average trading volume of 10,000 shares, the short-interest ratio is presently 4.2 days. Approximately 0.1% of the shares of the company are short sold.
View Valneva's Short Interest
.

When is Valneva's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VALN earnings forecast
.

What guidance has Valneva issued on next quarter's earnings?

Valneva issued an update on its FY 2024 earnings guidance on Wednesday, March, 20th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $172.2 million-$193.8 million, compared to the consensus revenue estimate of $245.0 million.

When did Valneva IPO?

Valneva (VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. served as the underwriters for the IPO.

How do I buy shares of Valneva?

Shares of VALN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VALN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners